ArticleBrain and behavior2025
COVID-19-Associated Cytotoxic Lesions of the Corpus Callosum in Chinese Patients: A Retrospective Study.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
background and purposeCytotoxic lesions of the corpus callosum (CLOCCs) are a rare clinicoradiologic syndrome, exceptionally rare in association with coronavirus disease (COVID-2019). This study aimed to investigate the neurological features of COVID-19-associated CLOCCs and gain insights into their underlying pathophysiology.
methodsA retrospective evaluation was conducted on patients with COVID-19-associated CLOCCs admitted to our neurological diseases unit. The evaluation included comprehensive analysis of clinical presentations, laboratory findings, and radiological data.
resultsFrom December 17, 2022, to December 31, 2023, our center identified CLOCCs in eight individuals with clinically established COVID-19 who underwent brain magnetic resonance imaging (MRI). The majority of patients (7/8) presented with fever preceding neurological symptoms. The spectrum of neurological findings encompassed altered consciousness (5/8), headache (4/8), cognitive and behavioral disturbances (4/8), ataxia (2/8), dysarthria (2/8), pyramidal signs (2/8), and visual impairments (2/8). Peripheral blood markers of inflammation and cytolysis revealed trends that paralleled disease progression. Elevated cerebrospinal fluid protein levels were observed in a single patient, whereas cell counts, glucose, and chloride levels were unremarkable. Treatment with glucocorticoids and antiviral medications led to complete clinical remission, with subsequent MRIs (7/8) showing radiological improvements within 3 days to 2 weeks posttreatment.
conclusionsOur study shows that CLOCCs associated with COVID-19 are characterized by a favorable prognosis and distinct MRI features, similar to those observed in other clinical contexts. This underscores the importance of including CLOCCs in the differential diagnosis of COVID-19 and highlights the need for ongoing research to address the neurological condition of SARS-CoV-2 infections and to inform preventive and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.